Exelixis Inc
Closed
SectorHealthcare
59.81 0.42
Overview
Share price change
24h
Min
59.53
Max
60.38
Income | 1.6M 212M |
|---|---|
Sales | 18M 629M |
P/E Sector Avg | 18.565 47.946 |
EPS | 0.82 |
Profit margin | 33.729 |
Employees | 1,077 |
EBITDA | -12M 263M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -12.63% downside |
Next Earnings | 3 Nov 2026 |
|---|
Market Cap | 742M 15B |
|---|---|
Previous open | 59.39 |
Previous close | 59.81 |
Exelixis Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Exelixis Inc Forecast
Price Target
By TipRanks
-12.63% downside
12 Months Forecast
Average 52.3 USD -12.63%
High 64 USD
Low 41 USD
Based on 13 Wall Street analysts offering 12 month price targets forExelixis Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
